Undisclosed ASD Program

About Translation-X

Translation-X is an early-stage, privately-held biotech company pioneering a novel approach to treating genetic disorders by modulating RNA translation. The company, spun out from Universität Basel, has secured significant non-dilutive grant funding from Swiss innovation agencies like Venture Kick and Innosuisse, indicating strong institutional validation. Its initial pipeline is focused on high-unmet-need neurological conditions, specifically Autism Spectrum Disorders, leveraging a proprietary platform. The company is currently in the pre-clinical research and development stage.

Therapeutic Areas

Other Autism Spectrum Disorders Drugs